Amplia Therapeutics Announces Rare Pathological Complete Response in Advanced Pancreatic Cancer Trial with Narmafotinib

Reuters

06/16

Amplia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Rare Pathological Complete Response in Advanced Pancreatic Cancer Trial with Narmafotinib

MELBOURNE, Australia, June 16, 2025 - Amplia Therapeutics Limited (ASX: ATX) has announced new data from its ongoing ACCENT clinical trial, which is evaluating the company's FAK inhibitor, narmafotinib, in combination with standard-of-care chemotherapies gemcitabine and Abraxane® for advanced pancreatic cancer. The trial has recorded a notable achievement with a patient exhibiting a pathological complete response (pCR), an uncommon occurrence in patients with metastatic pancreatic cancer. This result marks a significant milestone for the ACCENT trial, which continues to investigate the potential benefits of narmafotinib in treating advanced pancreatic cancer. Further details on the trial's findings and implications will be shared as the study progresses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN10656) on June 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2543679724"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543679724\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543679724?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543679724","market":"us","top_or_hot":-1,"title":"Amplia Therapeutics Announces Rare Pathological Complete Response in Advanced Pancreatic Cancer Trial with Narmafotinib","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Amplia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Rare Pathological Complete Response in Advanced Pancreatic Cancer Trial with Narmafotinib\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MELBOURNE, Australia, June 16, 2025 - Amplia Therapeutics Limited (ASX: ATX) has announced new data from its ongoing ACCENT clinical trial, which is evaluating the company's FAK inhibitor, narmafotinib, in combination with standard-of-care chemotherapies gemcitabine and Abraxane® for advanced pancreatic cancer. The trial has recorded a notable achievement with a patient exhibiting a pathological complete response (pCR), an uncommon occurrence in patients with metastatic pancreatic cancer. This result marks a significant milestone for the ACCENT trial, which continues to investigate the potential benefits of narmafotinib in treating advanced pancreatic cancer. Further details on the trial's findings and implications will be shared as the study progresses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/INNMF\">Amplia Therapeutics Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN10656) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics Announces Rare Pathological Complete Response in Advanced Pancreatic Cancer Trial with Narmafotinib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics Announces Rare Pathological Complete Response in Advanced Pancreatic Cancer Trial with Narmafotinib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-16 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Amplia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Rare Pathological Complete Response in Advanced Pancreatic Cancer Trial with Narmafotinib\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MELBOURNE, Australia, June 16, 2025 - Amplia Therapeutics Limited (ASX: ATX) has announced new data from its ongoing ACCENT clinical trial, which is evaluating the company's FAK inhibitor, narmafotinib, in combination with standard-of-care chemotherapies gemcitabine and Abraxane® for advanced pancreatic cancer. The trial has recorded a notable achievement with a patient exhibiting a pathological complete response (pCR), an uncommon occurrence in patients with metastatic pancreatic cancer. This result marks a significant milestone for the ACCENT trial, which continues to investigate the potential benefits of narmafotinib in treating advanced pancreatic cancer. Further details on the trial's findings and implications will be shared as the study progresses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/INNMF\">Amplia Therapeutics Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN10656) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDLc4DYfh:1","article_id":"2543679724","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543679724","pubTimestamp":1750071708,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MELBOURNE, Australia, June 16, 2025 - Amplia Therapeutics Limited  has announced new data from its ongoing ACCENT clinical trial, which is evaluating the company's FAK inhibitor, narmafotinib, in combination with standard-of-care chemotherapies gemcitabine and Abraxane for advanced pancreatic cancer. The trial has recorded a notable achievement with a patient exhibiting a pathological complete response , an uncommon occurrence in patients with metastatic pancreatic cancer. This result marks a significant milestone for the ACCENT trial, which continues to investigate the potential benefits of narmafotinib in treating advanced pancreatic cancer. Further details on the trial's findings and implications will be shared as the study progresses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","ATX.AU":"AMPLIA THERAPEUTICS LTD"},"translate_title":"Amplia Therapeutics宣布Narmafotinib在晚期胰腺癌试验中获得罕见的病理完全缓解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATX.AU":0.9},"content_text":"Amplia Therapeutics Announces Rare Pathological Complete Response in Advanced Pancreatic Cancer Trial with Narmafotinib\n    \n\n        MELBOURNE, Australia, June 16, 2025 - Amplia Therapeutics Limited (ASX: ATX) has announced new data from its ongoing ACCENT clinical trial, which is evaluating the company's FAK inhibitor, narmafotinib, in combination with standard-of-care chemotherapies gemcitabine and Abraxane® for advanced pancreatic cancer. The trial has recorded a notable achievement with a patient exhibiting a pathological complete response (pCR), an uncommon occurrence in patients with metastatic pancreatic cancer. This result marks a significant milestone for the ACCENT trial, which continues to investigate the potential benefits of narmafotinib in treating advanced pancreatic cancer. Further details on the trial's findings and implications will be shared as the study progresses.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN10656) on June 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}